Amphetamine Controlled-Release Prodrugs via Stereospecific Cuprate Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing amphetamine synthesis methods face challenges such as the production of undesired toxic aziridine derivatives, racemization, high toxicity and flammability of intermediates, and the need for controlled release and abuse-deterrent formulations with high chemical yield, selectivity, and low cost.
Innovation Solution
A controlled release, prodrug, and abuse-deterrent pharmaceutical composition is developed using stereospecific cuprate addition reactions with aziridine phosphoramidate compounds to produce highly pure amphetamine derivatives, ensuring high purity, low toxicity, and effective delivery systems.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If traditional amphetamine synthesis methods are used, then production cost and ease of manufacture are improved, but toxic aziridine derivatives and contaminants are generated
Solution Approach 1:
The patent extracts and removes the harmful aziridine ring structure from the synthesis pathway by using alternative starting materials that do not generate toxic aziridine derivatives as byproducts, thereby eliminating this specific harmful factor while maintaining manufacturing feasibility
Solution Approach 2:
The patent converts the synthesis approach to one where the desired amphetamine product is formed directly without generating harmful intermediates, turning the synthesis process into a cleaner, more beneficial operation that eliminates toxic byproducts rather than requiring their removal
2Productivity
If conventional synthesis routes are used, then manufacturing simplicity is maintained, but chemical yield and purity are reduced due to racemization
Solution Approach 1:
The patent employs preliminary chiral resolution or uses chiral auxiliaries in the synthesis pathway to establish the correct stereochemistry early in the process, preventing racemization and ensuring high optical purity of the final amphetamine product without requiring complex post-synthesis separation steps
Solution Approach 2:
The patent introduces chiral intermediates or catalysts that mediate the formation of the amphetamine molecule with controlled stereochemistry, allowing high enantiomeric excess to be achieved through the reaction mechanism itself rather than through complex separation processes
3Duration of action of moving object
If amphetamine is formulated for extended release, then duration of action is improved, but abuse potential may increase without proper deterrents
Solution Approach 1:
The patent formulates amphetamine as a prodrug composite that requires metabolic conversion to become active, combining the extended-release benefit with abuse deterrence since the prodrug form is not psychoactive and cannot be effectively abused through non-oral routes
Solution Approach 2:
The patent uses a prodrug approach where the inactive precursor is disposed of in the formulation, only converting to the active amphetamine form after oral ingestion and metabolic processing, thereby eliminating abuse potential while maintaining therapeutic duration of action
4Manufacturing precision
If high purity amphetamine is produced through multiple purification steps, then purity is improved, but productivity and manufacturing cost deteriorate
Solution Approach 1:
The patent performs chiral resolution or stereochemical control at an early stage in the synthesis pathway, establishing high optical purity before the final product formation, thereby eliminating the need for multiple purification steps and maintaining high productivity
Solution Approach 2:
The patent designs the synthesis route to naturally exclude formation of unwanted isomers or impurities through selective reaction pathways, requiring minimal purification steps to achieve high purity product and maintaining manufacturing efficiency
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides amphetamine formulations with reduced impurities, improved safety, and controlled release profiles, effectively addressing the challenges of synthesis and abuse deterrence while maintaining therapeutic efficacy.
Implementation Method 1
synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds
Implementation Method 2
deprotecting the chiral aryl or aryl-alkyl phosphoramidate amphetamine precursor under acidic conditions effective to produce a substituted amphetamine
Data Source
AI summary
The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.